Physician profile
Kim Hestand
NPI 1104356963
$2,511.26
in general payments reported to CMS, 2019-2025
24 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $530 · 2022: $385 · 2023: $501 · 2024: $643 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,596.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $643.73 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $305.95 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $278.25 | 2021-2024 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $269.57 | 2021-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $153.97 | 2021-2023 | Ozempic, Rybelsus |
| Biogen, INC. | $117.65 | 2024 | Zurzuvae |
| Glaxosmithkline, LLC. | $96.66 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $86.14 | 2021-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.90 | 2021-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $65.90 | 2021-2022 | |
| Amarin Pharma, INC. | $63.84 | 2021 | |
| Pfizer INC. | $61.94 | 2021-2024 | |
| Exact Sciences Corporation | $58.44 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lundbeck LLC | $34.19 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $33.79 | 2022-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $33.33 | 2023 | Xeomin |
| Neurelis, INC. | $20.44 | 2025 | Valtoco |
| Xeris Pharmaceuticals, INC. | $17.35 | 2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.88 | 2025 | Xifaxan |
| Smith+Nephew, INC. | $15.33 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.91 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $13.63 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $13.10 | 2021 | |
| Merck Sharp & Dohme LLC | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Hestand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.